Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children

被引:22
作者
Ono, Rintaro [1 ]
Hasegawa, Daisuke [1 ]
Hirabayashi, Shinsuke [1 ]
Kamiya, Takahiro [2 ]
Yoshida, Kenichi [1 ]
Yonekawa, Satoko [1 ]
Ogawa, Chitose [1 ,3 ]
Hosoya, Ryota [1 ]
Toki, Tsutomu [4 ]
Terui, Kiminori [4 ]
Ito, Etsuro [4 ]
Manabe, Atsushi [1 ]
机构
[1] St Lukes Int Hosp, Dept Pediat, Chuo Ku, Tokyo 1048560, Japan
[2] Natl Univ Singapore, Dept Pediat, Singapore 117548, Singapore
[3] Natl Canc Ctr, Dept Pediat Oncol, Tokyo, Japan
[4] Hirosaki Univ, Grad Sch Med, Dept Pediat, Hirosaki, Aomori, Japan
关键词
GATA1; Acute megakaryoblastic leukemia; Trisomy; 21; Transient abnormal myelopoiesis; TRANSIENT MYELOPROLIFERATIVE DISORDER; COOPERATIVE-STUDY GROUP; ACUTE MYELOID-LEUKEMIA; DOWN-SYNDROME; INHERITED MUTATION; CHILDHOOD; CYTARABINE; INFANTS; RISK; GENE;
D O I
10.1007/s00431-014-2430-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
GATA1 mutations are found almost exclusively in children with myeloid proliferations related to Down syndrome (DS). Here, we report two phenotypically and cytogenetically normal children with acute megakaryoblastic leukemia (AMKL) whose blasts had both acquired trisomy 21 and GATA1 mutation. Patient 1 was diagnosed with transient abnormal myelopoiesis in the neonatal period. Following spontaneous improvement of the disease, leukemic blasts increased 7 months later. He received less intensive chemotherapy, and he is now 6 years old in complete remission. Patient 2 was diagnosed with AMKL at the age of 18 months. Although he received intensive chemotherapy and a cord blood transplantation, he died without gaining remission. In both cases, trisomy 21 and GATA1 mutation were detected only in leukemic blasts, but not in germline samples. Based on a literature review, we identified reports describing 14 non-DS AMKL with GATA1 mutation and acquired trisomy 21. Of those, 12 cases were diagnosed during the neonatal period, whereas the remaining 2 cases were diagnosed at the age of 22 and 31 months, respectively. Conclusion: These cases suggest that GATA1 mutation may cooperate with the additional chromosome 21 in developing myeloid proliferations even in non-DS patients.
引用
收藏
页码:525 / 531
页数:7
相关论文
共 27 条
[1]   Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling [J].
Bourquin, JP ;
Subramanian, A ;
Langebrake, C ;
Reinhardte, D ;
Bernard, O ;
Ballerini, P ;
Baruchel, A ;
Cavé, H ;
Dastugue, N ;
Hasle, H ;
Kaspers, GL ;
Lessard, M ;
Michaux, L ;
Vyas, P ;
van Wering, E ;
Zwaan, CM ;
Golub, TR ;
Orkin, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (09) :3339-3344
[2]   GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder [J].
Carpenter, E ;
Valverde-Garduno, V ;
Sternberg, A ;
Mitchell, C ;
Roberts, I ;
Vyas, P ;
Vora, A .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (04) :548-551
[3]   Risk for leukemia in infants without down syndrome who have transient myeloproliferative disorder [J].
Cushing, Thomas ;
Clericuzio, Carol L. ;
Wilson, Carla S. ;
Taub, Jeffrey W. ;
Ge, Yubin ;
Reichard, Kaaren K. ;
Winter, Stuart S. .
JOURNAL OF PEDIATRICS, 2006, 148 (05) :687-689
[4]   Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder [J].
Gamis, Alan S. ;
Smith, Franklin O. .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (03) :277-287
[5]   Molecular lesions in childhood and adult acute megakaryoblastic leukaemia [J].
Hama, Asahito ;
Muramatsu, Hideki ;
Makishima, Hideki ;
Sugimoto, Yuka ;
Szpurka, Hadrian ;
Jasek, Monika ;
O'Keefe, Christine ;
Takahashi, Yoshiyuki ;
Sakaguchi, Hirotoshi ;
Doisaki, Sayoko ;
Shimada, Akira ;
Watanabe, Nobuhiro ;
Kato, Koji ;
Kiyoi, Hitoshi ;
Naoe, Tomoki ;
Kojima, Seiji ;
Maciejewski, Jaroslaw P. .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) :316-325
[6]   An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis [J].
Hollanda, Luciana M. ;
Lima, Carmen S. P. ;
Cunha, Anderson F. ;
Albuquerque, Dulcineia M. ;
Vassallo, Jose ;
Ozelo, Margareth C. ;
Joazeiro, Paulo P. ;
Saad, Sara T. O. ;
Costa, Fernando F. .
NATURE GENETICS, 2006, 38 (07) :807-812
[7]   Acute Megakaryoblastic Leukemia Without GATA1 Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome [J].
Inaba, Hiroto ;
Londero, Margherita ;
Maurer, Scott H. ;
Onciu, Mihaela ;
Ge, Yubin ;
Taub, Jeffrey W. ;
Rubnitz, Jeffrey E. ;
Raimondi, Susana C. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :E230-E233
[8]   Treatment and prognostic impact of transient leukemia in neonates with Down syndrome [J].
Klusmann, Jan-Henning ;
Creutzig, Ursula ;
Zimmermann, Martin ;
Dworzak, Michael ;
Jorch, Norbert ;
Langebrake, Claudia ;
Pekrun, Amulf ;
Macakova-Reinhardt, Katarina ;
Reinhardt, Dirk .
BLOOD, 2008, 111 (06) :2991-2998
[9]   Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with down syndrome and acute myeloid leukemia: The Japanese childhood AML cooperative study group [J].
Kudo, Kazuko ;
Kojima, Seiji ;
Tabuchi, Ken ;
Yabe, Hiromasa ;
Tawa, Akio ;
Imaizumi, Masue ;
Hanada, Ryoji ;
Hamamoto, Kazuko ;
Kobayashi, Ryoji ;
Morimoto, Akira ;
Nakayama, Hideki ;
Tsuchida, Masahiro ;
Horibe, Keizo ;
Kigasawa, Hisato ;
Tsukimoto, Ichiro .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (34) :5442-5447
[10]   Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy [J].
Kudo, Kazuko ;
Hama, Asahito ;
Kojima, Seiji ;
Ishii, Ruriko ;
Morimoto, Akira ;
Bessho, Fumio ;
Sunami, Shosuke ;
Kobayashi, Naoyuki ;
Kinoshita, Akitoshi ;
Okimoto, Yuri ;
Tawa, Akio ;
Tsukimoto, Ichiro .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (04) :630-635